Obsidian Therapeutics Inc. (OBX)
OBX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | OBX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0002130606 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$100.6M |
| Operating income | -$105.7M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $40.4M |
| Total assets | $88.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $66.5M cash; operating cash flow $0 a quarter. | Report 2026-06-30 |
| Shares outstanding | 61,774,046 (2026-11-09). | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months | 8-K 4.01 2026-08-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$50.7M | Not filed | $66.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | $0 | $0 | $0 | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q3 2026 2026-03-31 | Not filed | -$19.6M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-09-30 | $0 | -$28.5M | Not filed | $37.4M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-06-30 | Not filed | -$26.9M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-03-31 | Not filed | -$25.0M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-11-12 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 44 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.4% |
| 1 month | +4.8% |
| 3 months | -33.6% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -64.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ARDX | Ardelyx Inc. | $3.07 | -0.65% | $771.7M |
| LXRX | Lexicon Pharmaceuticals Inc. | $1.75 | -2.23% | $779.2M |
| ORIC | Oric Pharmaceuticals Inc. | $7.52 | -4.33% | $779.5M |
| IVA | Inventiva S.A. American Depository Shares | $3.32 | -9.78% | $784.5M |
| COLL | Collegium Pharmaceutical Inc. | $25.43 | +0.43% | $790.2M |
| IRWD | Ironwood Pharmaceuticals Inc. | $4.85 | +0.41% | $802.9M |
| SGMT | Sagimet Biosciences Inc. Series A | $10.13 | -0.88% | $723.0M |
| SNDX | Syndax Pharmaceuticals Inc. | $9.13 | -3.39% | $821.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier